Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment.

@article{Kuipers2006OpenlabelSO,
  title={Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment.},
  author={Mirjam Kuipers and Ronald A. Smulders and Walter J. J. Krauwinkel and Timothy J Hoon},
  journal={Journal of pharmacological sciences},
  year={2006},
  volume={102 4},
  pages={405-12}
}
Determining the pharmacokinetics and safety of solifenacin succinate, a once-daily, oral antimuscarinic agent indicated for treatment of overactive bladder, in subjects with hepatic impairment. In this open-label study, 16 subjects (eight with moderate hepatic impairment [defined as a Child-Pugh score of 7 - 9], eight healthy) received a single oral 10 mg… CONTINUE READING